Cancers
Tarlatamab in Small Cell Lung Cancer and Extrapulmonary Small Cell Carcinoma: A Single-Centre Retrospective Cohort Study of Routine-Practice Outcomes
By Ayrton Bangolo, Lili Zhang, Jiahe Zhao and 22 others.
Abstract
Background
Tarlatamab, a Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE), has demonstrated significant efficacy in relapsed small cell lung cancer (SCLC) in clinical trials. However, real-world clinical outcomes and its efficacy in extrapulmonary small cell carcinoma (EPSCC) remain sparsely characterized.